The global valvular heart diseases market is anticipated to grow at a considerable CAGR of around 8.0% during the forecast period (2021-2027). Valvular heart disease is categorized by deficiency or any damage in one of the four heart valves, namely, aortic, tricuspid or pulmonary, and mitral. Adult cardiac surgery such as treatment for valvular heart diseases is growing at a rapid pace. Valvular heart disease can be diagnosed by chest x-ray, electrocardiogram, cardiac catheterization, stress testing, and other diagnosis procedure. Valvular heart disease can be treated by medication or surgery. The major factor that drives the growth of the market includes the increasing prevalence of coronary artery diseases, cardiovascular diseases, and heart attack. The change in lifestyle, obesity and extreme consumption of alcohol boost the market growth. Additionally, according to the World Health Organization (WHO), cardiovascular disease is one of the main reasons for mortality across the globe. CVDs cause around 17.9 million deaths across the globe each year.
Browse the full report description of "Global Valvular Heart Diseases Market Size, Share & Trends Analysis by Diseases (Aortic Valve Replacement, Heart Valve Disease, Mitral Valve Stenosis, and Others), By Diagnosis (Cardiac Catheterization, Electrocardiogram (ECG), Chest X-Ray, Stress Testing, Others), By Treatment (Medication and Surgery), By End-Users (Hospital & Clinics, Ambulatory Surgical Centers, and Research Institutes) Forecast, 2021-2027" at https://www.omrglobal.com/industry-reports/valvular-heart-diseases-treatment-market
Moreover, to gain major market share in the market the key players operating in the global valvular heart diseases market had been adopting strategies such as product expansion, drug launch, and the US FDA approval. For instance, In December 2019, CryoLife, Inc. had received approval from the US Food and Drug Administration (FDA) for Investigational New Drug (IND) application to initiate the PROACT Xa clinical trial, The trial is to regulate if patients with an On-X mechanical aortic valve can be sustained safely and efficiently on apixaban rather than warfarin.
Market Coverage
o By Diseases
o By Diagnosis
o ByTreatment
o By End-User
o North America
o Europe
o Asia-Pacific
o Rest of the World
Key questions addressed by the report
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
Global Valvular Heart Diseases Market
By Diseases
By Diagnosis
By Treatment
By End-User
Global Valvular Heart Diseases Market by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/valvular-heart-diseases-treatment-market